View Older Stories View More Recent Stories

Sep 28, 2017 08:00AM Patient Groups Sharpen Their Capabilities to Protect Access to Medicines for Treating Rare Bleeding Disorders
Sep 19, 2017 10:30AM CSL Behring Will Help Transform Biotech Education and Research with $4.92 Million Gift to Penn State
Sep 14, 2017 07:50PM CSL Behring Announces FDA Approval of Privigen® [Immune Globulin Intravenous (Human), 10% Liquid] for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Adults
Sep 14, 2017 05:28AM CSL Behring Joins Together With Conference Attendees to Make Donation to IPOPI
Aug 28, 2017 08:39AM CSL Behring to Acquire Biotech Company Calimmune and its Proprietary Stem Cell Gene Therapy Platform
Jul 25, 2017 08:00AM HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human]) Now Available in the United States for Patients with Hereditary Angioedema
Jul 21, 2017 09:54AM CSL Behring Receives Orphan-Drug Exclusivity for HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human])
Jul 19, 2017 09:30AM FDA Accepts CSL Behring's Supplemental Biologics License Application for Hizentra® Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Indication
Jul 12, 2017 09:00AM New Data Demonstrate Prophylactic Treatment with IDELVION® Reduces Bleed Frequency and Has Potential to Positively Impact Patients with Haemophilia B
Jul 11, 2017 06:30AM CSL Behring Awards Researchers to Advance Immunoglobulin Therapy in Treating Neurological Disorders
Jul 10, 2017 09:00AM New Findings Show AFSTYLA® Provides Long-lasting Efficacy without Increased Product Consumption for Prophylactic and On-Demand Treatment of Haemophilia A
Jul 6, 2017 09:00AM New Data for Two Leading Haemophilia Medicines -- AFSTYLA® and IDELVION® -- to be Presented at the International Society on Thrombosis and Haemostasis Congress 2017
Jun 23, 2017 02:16PM FDA Approves HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human]), First and Only Subcutaneous Preventive Treatment for Hereditary Angioedema
May 19, 2017 08:00AM New Innovation in the Fight Against Hemophilia Earns CSL Behring the NORD 2017 Industry Innovation Award
Apr 25, 2017 08:06AM Wirecard North America and CSL Plasma Launch First Cash-Back Donor Prepaid Card
Apr 19, 2017 02:00PM Therapeutic Goods Administration Approves AFSTYLA® - CSL Behring's Novel Recombinant Haemophilia A Treatment
Apr 10, 2017 11:00AM Improving Access to Lifesaving Treatments for Bleeding Disorders in the Developing World
Mar 31, 2017 10:00AM Jeffrey Modell Foundation to Open the First North African Network for Primary Immunodeficiencies
Mar 29, 2017 03:30PM CSL Behring Awards Grant To Patient Groups To Develop Innovative Ways To Advocate For Patients
Mar 29, 2017 10:00AM Jeffrey Modell Foundation to Open the First North African Network for Primary Immunodeficiencies
Mar 22, 2017 05:16PM New England Journal of Medicine Publishes Pivotal Phase III Data for CSL Behring's Subcutaneous C1-Esterase Inhibitor in HAE Patients
Mar 1, 2017 09:25AM Largest Ever CIDP Clinical Study Completed
Feb 14, 2017 09:30AM FDA Accepts CSL Behring's Biologics License Application Supplement for Using Privigen® to Treat Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), a Rare Neurological Condition
Jan 9, 2017 09:55AM AFSTYLA®, for Haemophilia A, Receives European Commission Approval
Dec 14, 2016 01:58PM Health Canada Approves CSL Behring's AFSTYLA™ for the Treatment of Hemophilia A
Dec 3, 2016 08:30PM CSL Behring Presents New Phase III Analysis of IDELVION® for Hemophilia B at the 2016 American Society of Hematology Annual Meeting
Dec 2, 2016 09:51AM The Lancet Respiratory Medicine Publishes RAPID Extension Study Data on Effect of Zemaira® [Alpha1-Proteinase Inhibitor (Human)] in Patients with Alpha-1 Antitrypsin Deficiency (AATD)
Nov 15, 2016 01:25PM CSL Behring Presents Positive Results from the CSL112 AEGIS-I Phase 2b Trial
Nov 14, 2016 10:00AM AFSTYLA®, for Haemophilia A, Receives Positive Opinion from European Medicines Agency CHMP
Oct 27, 2016 02:30PM CSL Behring Receives 2016 Marcum Innovator Breakthrough Award for Pioneering New Advancements in the Biotech/Healthcare Field
Oct 7, 2016 03:00PM Many Rare Disease Patients Would Not Have Treatments Available to Them without an Adequate Supply of Human Plasma
Sep 29, 2016 09:46AM Japan's Ministry of Health, Labour and Welfare (MHLW) Approves CSL Behring's IDELVION® -- The First and Only Hemophilia B Therapy with Up to 14-day Dosing Intervals
Aug 30, 2016 09:00AM FDA Accepts CSL Behring's Biologics License Application for First Subcutaneous Prophylactic Therapy to Prevent Hereditary Angioedema Attacks
Aug 30, 2016 09:00AM FDA Accepts CSL Behring's Biologics License Application for First Subcutaneous Prophylactic Therapy to Prevent Hereditary Angioedema Attacks
Jul 27, 2016 10:00AM CSL Behring Presents Pivotal Efficacy Data for AFSTYLA® In Adolescents and Children with Hemophilia A at the World Federation of Hemophilia 2016 World Congress
Jul 26, 2016 10:00AM CSL Behring Presents Phase III Data for IDELVION® for Hemophilia B at the World Federation of Hemophilia 2016 World Congress
Jul 25, 2016 11:00AM CSL Behring Awards Emerging Coagulation Specialists Across the Globe to Support Advancements in the Care of Patients with Bleeding Disorders
Jul 20, 2016 11:18AM CSL Plasma Raises Over $118,000 For The Immune Deficiency Foundation
Jul 19, 2016 10:00AM CSL Behring to Present New Data for IDELVION® and AFSTYLA® at the World Federation of Hemophilia 2016 World Congress
Jul 18, 2016 11:55AM U.S. FDA Approves CSL Behring's Berinert® as the First and Only Pediatric Treatment for Hereditary Angioedema (HAE)
Jun 23, 2016 05:30AM CSL Behring Announces Immunoglobulin Research Grant Winners
Jun 20, 2016 09:00AM AFSTYLA® - CSL Behring's Novel Recombinant Factor VIII Single Chain Therapy for Hemophilia A - Now Available in the U.S.
May 26, 2016 03:20PM U.S. FDA Approves CSL Behring's AFSTYLA® -- The First and Only Recombinant Factor VIII Single Chain Therapy for Hemophilia A
May 13, 2016 10:15AM CSL's Paul Perreault Receives Healthcare CEO Enterprise Award from Philadelphia Alliance for Capital and Technologies
May 11, 2016 01:30PM IDELVION® -- CSL Behring's Innovative Therapy for Hemophilia B Patients -- Receives 7 Years of Marketing Exclusivity from the U.S. Food and Drug Administration
May 11, 2016 11:00AM European Commission Approves IDELVION® --CSL Behring's Novel Hemophilia B Treatment with Up to 14-day Dosing Intervals
May 3, 2016 10:00AM CSL CEO Paul Perreault Focuses on Patient-Centric Leadership in Pharma
Apr 25, 2016 09:00AM CSL Behring Commemorates 100 Years of Delivering on its Promise to Develop Innovative Therapies for People with Life-threatening Medical Conditions
Apr 13, 2016 09:12AM CSL Behring Marks World Hemophilia Day by Donating IUs of Its Specialty Biotherapeutics for Bleeding Disorders to World Federation of Hemophilia
Mar 21, 2016 09:18AM IDELVION® for Hemophilia B Now Available in the U.S.
View More Recent Stories View Older Stories